- https://www.sec.gov/Archives/edgar/data/1121404/000119312523181686/d462679d6k.htm
- https://www.sec.gov/Archives/edgar/data/1121404/000110465923075738/tm2319553d2_11k.htm
- https://www.sec.gov/Archives/edgar/data/1121404/000110465923075737/tm2319553d1_11k.htm
- https://www.sec.gov/Archives/edgar/data/1121404/000119312523169820/d511072d6k.htm
- https://www.sec.gov/Archives/edgar/data/1121404/000119312523159555/d497289d6k.htm
Sanofi
SNY
The U.S. Food and Drug Administration on Monday approved a Sanofi SNY and AstraZeneca PLC AZN respiratory syncytial virus vaccine for newborns and infants. The RSV vaccine, Beyfortus, was approved for prevention of RSV lower respiratory tract disease in babies entering their first RSV vaccine as well as children up to two years old who remain vulnerable to severe RSV, the FDA said in a release. RSV typically causes mild, cold-like symptoms but can be serious, particularly in infants and older adults. AstraZeneca’s ADR was down 0.6% on Monday, while Sanofi’s ADR was up 0.2%.
SNY
undefinedYES
The FDA approval of Sanofi's RSV vaccine for newborns and infants is a positive development for the company.
Consider a long call option strategy to potentially profit from a rise in Sanofi's stock price.
AZN
NO
undefinedAstraZeneca's stock was down 0.6% on the day of the announcement, indicating a negative market reaction.
Consider a long put option strategy to potentially profit from a decline in AstraZeneca's stock price.